复星医药：拟参与设立私募股权投资基金并筹划转让上海克隆100%股权

Core Viewpoint - Fosun Pharma (600196.SH) announced plans to transfer 100% equity of Shanghai Clone, with the proceeds aimed at continuous investment in innovative drug business [1] Group 1: Equity Transfer - Fosun Pharma's subsidiary intends to transfer 100% equity of Shanghai Clone [1] - The transfer is expected to generate proceeds of up to 1.256 billion yuan [1] Group 2: Fund Establishment - Fosun Pharma's subsidiary plans to invest 54.6 million yuan as a limited partner (LP) to establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance [1] - After the establishment of the special fund, Fosun Pharma's subsidiary is expected to hold a 9.98% share of the fund's assets [1]